Oncimmune Holdings (LSE:ONC) EV-to-EBIT : -6.52 (As of Jun. 05, 2024)

Oncimmune Holdings EV-to-EBIT Chart

Oncimmune Holdings Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	Aug23
EV-to-EBIT		Get a 7-Day Free Trial					-6.23	-7.84	-27.75	-8.84	-3.56

Oncimmune Holdings Semi-Annual Data
	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Nov19	May20	Nov20	May21	Nov21	May22	Feb23	Aug23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-	-8.84	-	-3.56	-

Competitive Comparison of Oncimmune Holdings's EV-to-EBIT

For the Biotechnology subindustry, Oncimmune Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncimmune Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's EV-to-EBIT falls into.

Oncimmune Holdings EV-to-EBIT Calculation

Oncimmune Holdings's EV-to-EBIT for today is calculated as:

Oncimmune Holdings's current Enterprise Value is £17.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncimmune Holdings's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was £-2.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncimmune Holdings  (LSE:ONC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oncimmune Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Oncimmune Holdings's Enterprise Value for the quarter that ended in Feb. 2024 was £20.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncimmune Holdings's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was £-2.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncimmune Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncimmune Holdings (LSE:ONC) Business Description